Why the study?
Can matrix metalloproteinases serve as predictive biomarkers to support the diagnosis of atherosclerosis?
Can matrix metalloproteinases serve as predictive biomarkers to support the diagnosis of atherosclerosis?
Answers are grounded in this paper and cite their sources.
Matrix metalloproteinases are closely related to vascular wall remodeling and may serve as predictive biomarkers for the diagnosis of subclinical atherosclerosis.
Cardiovascular diseases represent the main cause of morbidity and mortality in the world and are epidemic events involving the atherosclerosis and coronary artery disease in particular. There are a wide variety of factors and markers associated with the development and aggravation of these diseases, including atherosclerosis. Subclinical Atherosclerosis can be determined by serum inflammatory markers present in the atherogenic process. Such markers can take a direct or indirect indicator role on atherosclerotic cardiovascular disease. The extracellular matrix metalloproteinases are biomarkers closely related into modifying and remodeling of vascular wall and other tissues and can represent predictive value patterns to support diagnosis. This review discusses the function and types of matrix metalloproteinases and its use as an indicator of support for the diagnosis of atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Fonseca et al. (2014) conducted a review in Atherosclerosis. Matrix metalloproteinases was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: